Our brain depends on a constant source of energy from adenosine triphosphate (ATP). Crucial to ATP production is a molecule called nicotinamide adenine dinucleotide (NAD+). Unfortunately, in neurodegenerative diseases such as multiple sclerosis and Parkinson’s disease, the NAD+/NADH ratio (an indicator of brain energy capacity) declines at an alarming rate.
Researchers at UT Southwestern Medical Center have developed a concentrated suspension of gold nanocrystals called CNM-Au8. These nanocrystals act as catalysts, accelerating the conversion of NADH to NAD+, potentially increasing energy stores in the brain. Research has shown that CNM-Au8 can cross the blood-brain barrier and penetrate cell membranes, delivering its effects directly to where it is needed.
Two separate studies included patients with MS and Parkinson’s. Participants were given daily doses of CNM-Au8 for 12 weeks, and researchers monitored key brain energy metabolites. After treatment, both groups experienced a statistically significant increase in the NAD+/NADH ratio; This shows that the nanocrystals actually target brain function.
The PD study also noted statistically significant improvements in activities of daily living, indicating potential functional benefit for patients. Side effects were reported as mild to moderate, increasing optimism about this treatment approach.
Although these results are encouraging, they represent only a phase 2 trial. Larger phase 3 studies are needed to confirm the efficacy and safety of CNM-Au8 in larger patient populations.
News materials cannot be equated with a doctor’s prescription. Consult an expert before making a decision.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
